{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:57:53Z","timestamp":1767902273314,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation of China","award":["No.7212032"],"award-info":[{"award-number":["No.7212032"]}]},{"name":"Training Program of the National Natural Science Foundation of China","award":["GPY201703"],"award-info":[{"award-number":["GPY201703"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neuroblastoma (NB) is the most common extracranial solid tumor in children. It is known for high heterogeneity and concealed onset. In recent years, the mechanism of its occurrence and development has been gradually revealed. The purpose of this study is to summarize the clinical characteristics of children with NB and abnormal chromosome 10, and to investigate the relationship between the number and structure of chromosome 10 abnormalities and NB prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Chromosome G-banding was used at the time of diagnosis to evaluate the genetics of chromosomes in patients with NB and track their clinical characteristics and prognosis. All participants were diagnosed with NB in the Medical Oncology Department of the Beijing Children\u2019s Hospital from May 2015 to December 2018 and were followed up with for at least 1 year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of all 150 patients with bone marrow metastases, 42 were clearly diagnosed with chromosomal abnormalities. Thirteen patients showed abnormalities in chromosome 10, and chromosome 10 was the most commonly missing chromosome. These 13 patients had higher LDH and lower OS and EFS than children with chromosomal abnormalities who did not have an abnormality in chromosome 10. Eight patients had both MYCN amplification and 1p36 deletion. Two patients had optic nerve damage and no vision, and one patient had left supraorbital metastases 5 months after treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results indicated that chromosome 10 might be a new prognostic marker for NB. MYCN amplification and 1p36 deletion may be related to chromosome 10 abnormalities in NB. Additionally, NB patients with abnormal chromosome 10 were prone to orbital metastases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13052-021-01085-6","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:47:49Z","timestamp":1623250069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis"],"prefix":"10.1186","volume":"47","author":[{"given":"Chi-yi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-lin","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-xia","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-4944","authenticated-orcid":false,"given":"Xiao-li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"issue":"3","key":"1085_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc1014","volume":"3","author":"GM Brodeur","year":"2003","unstructured":"Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203\u201316. https:\/\/doi.org\/10.1038\/nrc1014.","journal-title":"Nat Rev Cancer"},{"key":"1085_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.semcancer.2019.09.017","volume":"69","author":"FH Pottoo","year":"2019","unstructured":"Pottoo FH, Barkat MA, Harshita AMA, Javed MN, QMS J, et al. Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Semin Cancer Biol. 2019;69:100.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1085_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/14737140.2017.1285230","volume":"17","author":"S Whittle","year":"2017","unstructured":"Whittle S, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369\u201386. https:\/\/doi.org\/10.1080\/14737140.2017.1285230.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1085_CR4","doi-asserted-by":"publisher","unstructured":"Malis J. Clinical presentation of neuroblastoma. Neuroblastoma. 2013. https:\/\/doi.org\/10.5772\/55921.","DOI":"10.5772\/55921"},{"issue":"12","key":"1085_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrclinonc.2014.168","volume":"11","author":"GM Brodeur","year":"2014","unstructured":"Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol. 2014;11(12):704\u201313. https:\/\/doi.org\/10.1038\/nrclinonc.2014.168.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1085_CR6","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.jpedsurg.2016.07.003","volume":"51","author":"Y Chen","year":"2016","unstructured":"Chen Y, Tsai YH, Tseng BJ, Pan HY, Tseng SH, et al. Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells. J Pediatr Surg. 2016;51(11):1818\u201325. https:\/\/doi.org\/10.1016\/j.jpedsurg.2016.07.003.","journal-title":"J Pediatr Surg"},{"issue":"17","key":"1085_CR7","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1158\/1078-0432.CCR-07-4461","volume":"14","author":"S Bilke","year":"2008","unstructured":"Bilke S, Chen QR, Wei JS, Khan J. Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification. Clin Cancer Res. 2008;14(17):5540\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4461.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1085_CR8","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","volume":"11","author":"GM Brodeur","year":"1993","unstructured":"Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466\u201377. https:\/\/doi.org\/10.1200\/JCO.1993.11.8.1466.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1085_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","volume":"27","author":"SL Cohn","year":"2009","unstructured":"Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27(2):289\u201397. https:\/\/doi.org\/10.1200\/JCO.2008.16.6785.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1085_CR10","first-page":"466","volume":"111","author":"CK Leung","year":"1998","unstructured":"Leung CK. Fifteen years\u2019 review of advanced childhood neuroblastoma from a single institution in Hong Kong. Chin Med J. 1998;111(5):466\u20139.","journal-title":"Chin Med J"},{"issue":"6","key":"1085_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40272-017-0251-3","volume":"19","author":"F Berthold","year":"2017","unstructured":"Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979-2015. Paediatr Drugs. 2017;19(6):577\u201393. https:\/\/doi.org\/10.1007\/s40272-017-0251-3.","journal-title":"Paediatr Drugs"},{"key":"1085_CR12","first-page":"178","volume":"28","author":"M Xiaoli","year":"2013","unstructured":"Xiaoli M, Mei J, Dawei Z, et al. Clinical features and recent treatment effect analysis of 91 neuroblastoma patients with multidisciplinary treatment. J Appl Clin Pediatr. 2013;28:178\u201382.","journal-title":"J Appl Clin Pediatr"},{"key":"1085_CR13","first-page":"105","volume":"35","author":"SK Sidhu","year":"2018","unstructured":"Sidhu SK, Ramalingam K, Goyal S, Poonia M, Poonia M, Rajawat GS, et al. Comparing the efficacy of Leishman-Giemsa cocktail stain, Giemsa stain, and Papanicolaou stain in potentially malignant Oral lesions: a study on 540 cytological samples. JCytol. 2018;35:105\u20139.","journal-title":"JCytol."},{"issue":"5","key":"1085_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/gcc.22827","volume":"59","author":"L Amoroso","year":"2020","unstructured":"Amoroso L, Ognibene M, Morini M, Conte M, Cataldo AD, Tondo A, et al. Genomic coamplification of CDK4\/MDM2\/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients. Genes Chromosom Cancer. 2020;59(5):277\u201385. https:\/\/doi.org\/10.1002\/gcc.22827.","journal-title":"Genes Chromosom Cancer"},{"issue":"3","key":"1085_CR15","doi-asserted-by":"publisher","first-page":"e59268","DOI":"10.1371\/journal.pone.0059268","volume":"8","author":"G Lundberg","year":"2013","unstructured":"Lundberg G, Jin Y, Sehic D, \u00d8ra I, Versteeg R, Gisselsson D. Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state. PLoS One. 2013;8(3):e59268. https:\/\/doi.org\/10.1371\/journal.pone.0059268.","journal-title":"PLoS One"},{"issue":"1","key":"1085_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2407-9-44","volume":"9","author":"C Lavarino","year":"2009","unstructured":"Lavarino C, Cheung NK, Garcia I, Domenech D, Torres C, Alaminos M, et al. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer. 2009;9(1):44. https:\/\/doi.org\/10.1186\/1471-2407-9-44.","journal-title":"BMC Cancer"},{"issue":"5","key":"1085_CR17","doi-asserted-by":"publisher","first-page":"e27635","DOI":"10.1002\/pbc.27635","volume":"66","author":"S Parodi","year":"2019","unstructured":"Parodi S, Pistorio A, Erminio G, Ognibene M, Morini M, Garaventa A, et al. Loss of whole chromosome X predicts prognosis of neuroblastoma patients with numerical genomic profile. Pediatr Blood Cancer. 2019;66(5):e27635. https:\/\/doi.org\/10.1002\/pbc.27635.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1085_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","volume":"144","author":"PJ Stephens","year":"2011","unstructured":"Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27\u201340. https:\/\/doi.org\/10.1016\/j.cell.2010.11.055.","journal-title":"Cell."},{"issue":"1","key":"1085_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1096\/fj.201901205RR","volume":"34","author":"C Wang","year":"2020","unstructured":"Wang C, Feng Y, Zhang C, Cheng D, Wu R, Yang Y, et al. PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer. FASEB J. 2020;34(1):1304\u201318. https:\/\/doi.org\/10.1096\/fj.201901205RR.","journal-title":"FASEB J"},{"issue":"3","key":"1085_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/pros.10038","volume":"50","author":"B Leube","year":"2002","unstructured":"Leube B, Drechsler M, M\u00fchlmann K, Sch\u00e4fer R, Schulz WA, Santourlidis S, et al. Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer. Prostate. 2002;50(3):135\u201344. https:\/\/doi.org\/10.1002\/pros.10038.","journal-title":"Prostate."},{"issue":"4","key":"1085_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.biocel.2008.09.022","volume":"41","author":"BL Stiles","year":"2009","unstructured":"Stiles BL. Phosphatase and tensin homologue deleted on chromosome 10: extending its PTEN tacles. Int J Biochem Cell Biol. 2009;41(4):757\u201361. https:\/\/doi.org\/10.1016\/j.biocel.2008.09.022.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"1085_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.bbrc.2018.12.169","volume":"510","author":"Z Li","year":"2019","unstructured":"Li Z, Xie J, Fei Y, Gao P, Xie Q, Gao W, et al. GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN. Biochem Biophys Res Commun. 2019;510(3):339\u201344. https:\/\/doi.org\/10.1016\/j.bbrc.2018.12.169.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"1085_CR23","first-page":"1761","volume":"62","author":"J Mora","year":"2002","unstructured":"Mora J, Cheung NK, Oplanich S, Chen L, Gerald WL. Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Res. 2002;62(6):1761\u20137.","journal-title":"Cancer Res"},{"issue":"5","key":"1085_CR24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00401-018-1905-0","volume":"136","author":"D Stichel","year":"2018","unstructured":"Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018;136(5):793\u2013803. https:\/\/doi.org\/10.1007\/s00401-018-1905-0.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1085_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cancergencyto.2006.08.014","volume":"174","author":"P L\u00e1zcoz","year":"2007","unstructured":"L\u00e1zcoz P, Mu\u00f1oz J, Nistal M, Pesta\u00f1a A, Enc\u00edo IJ, Castresana JS. Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet. 2007;174(1):1\u20138. https:\/\/doi.org\/10.1016\/j.cancergencyto.2006.08.014.","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"1085_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3171\/jns.2002.97.6.1397","volume":"97","author":"M Sanson","year":"2002","unstructured":"Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartalat-Carel S, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg. 2002;97(6):1397\u2013401. https:\/\/doi.org\/10.3171\/jns.2002.97.6.1397.","journal-title":"J Neurosurg"},{"issue":"5","key":"1085_CR27","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3892\/or.2018.6287","volume":"39","author":"HS Park","year":"2018","unstructured":"Park HS, Kim BC, Yeo HY, Kim KH, Yoo BC, Park JW, et al. Deleted in malignant brain tumor 1 is a novel prognostic marker in colorectal cancer. Oncol Rep. 2018;39(5):2279\u201387. https:\/\/doi.org\/10.3892\/or.2018.6287.","journal-title":"Oncol Rep"},{"issue":"1","key":"1085_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/neuonc\/noy120","volume":"21","author":"AK Park","year":"2019","unstructured":"Park AK, Kim P, Ballester LY, Esquenazi Y, Zhao Z. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Neuro-Oncology. 2019;21(1):59\u201370. https:\/\/doi.org\/10.1093\/neuonc\/noy120.","journal-title":"Neuro-Oncology"},{"issue":"2","key":"1085_CR29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5114\/aoms.2017.69374","volume":"15","author":"D Jesionek-Kupnicka","year":"2019","unstructured":"Jesionek-Kupnicka D, Braun M, Tr\u0105bska-Kluch B, Czech J, Szybka M, Szyma\u0144ska B, et al. MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients. Arch Med Sci. 2019;15(2):504\u201312. https:\/\/doi.org\/10.5114\/aoms.2017.69374.","journal-title":"Arch Med Sci"},{"issue":"2","key":"1085_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/0008-5472.CAN-17-1153","volume":"78","author":"TM Campbell","year":"2018","unstructured":"Campbell TM, Castro MAA, de Oliveira KG, Ponder BAJ, Meyer KB. ER\u03b1 binding by transcription factors NFIB and YBX1 enables FGFR2 signaling to modulate estrogen responsiveness in breast Cancer. Cancer Res. 2018;78(2):410\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1153.","journal-title":"Cancer Res"},{"issue":"29","key":"1085_CR31","doi-asserted-by":"publisher","first-page":"17753","DOI":"10.1074\/jbc.M115.661066","volume":"290","author":"Y Huang","year":"2015","unstructured":"Huang Y, Hamana T, Liu J, Wang C, An L, You P, et al. Type 2 fibroblast growth factor receptor signaling preserves Stemness and prevents differentiation of prostate stem cells from the basal compartment. J Biol Chem. 2015;290(29):17753\u201361. https:\/\/doi.org\/10.1074\/jbc.M115.661066.","journal-title":"J Biol Chem"},{"key":"1085_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/978-1-4939-6703-2_24","volume":"1541","author":"M Stevens-Kroef","year":"2017","unstructured":"Stevens-Kroef M, Simons A, Rack K, Hastings RJ. Cytogenetic nomenclature and reporting. Methods Mol Biol. 2017;1541:303\u20139. https:\/\/doi.org\/10.1007\/978-1-4939-6703-2_24.","journal-title":"Methods Mol Biol"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-01085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-021-01085-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-01085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:52:11Z","timestamp":1623250331000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-021-01085-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1186\/s13052-021-01085-6","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"9 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Beijing Children\u2019s Hospital of Capital Medical University approved this study (2019-k-390). Informed consent was acquired from all participants and their parents prior to the collection of samples and information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants provided informed consent for the publication of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this study report no conflicts of interest or additional funding support.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}